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The psoriatic in¯ammatory process is characterized
by an overexpression of pro-in¯ammatory cytokines
such as tumor necrosis factor-a and interleukin-1b
compared with a relative de®ciency of anti-in¯am-
matory factors such as interleukin-10 and the inter-
leukin-1 receptor antagonist (interleukin-1Ra). Gene
polymorphisms that affect cytokine production may
contribute to the disease-associated cytokine imbal-
ance and in¯uence susceptibility to psoriasis. Here,
we investigated the relationship between polymorph-
isms in the genes encoding for tumor necrosis fac-
tor-a (G±238A, G±308A), interleukin-1b (C±511T,
T+3953C), and interleukin-1Ra (intron 2), and cyto-
kine production in peripheral blood mononuclear
cells of healthy donors, and analyzed the distribution
of these polymorphisms in patients with psoriasis
vulgaris (n = 231) and healthy controls (n = 345).
Carriage of tumor necrosis factor A±238 allele 2
(±238*A) was associated with increased production of
tumor necrosis factor-a in response to lipopolysac-
charide in vitro, and with early onset disease (< 40 y),
especially in male patients with psoriasis [32% vs 7%
in male controls; odds ratio = 6.78, 95% con®dence
interval = (3.18±15.15), padjusted = 2 3 10
±7]. Carriage
of the interleukin-1B±511*1 (±511*C) homozygous
genotype was associated with increased production
of interleukin-1Ra in response to lipopolysaccharide
and interleukin-10, and with late onset psoriasis
[> 40 y; 61% vs 44% in controls; odds ratio = 2.04,
95% con®dence interval = (1.19±3.53), padjusted
= 0.0419]. These ®ndings indicate that gene poly-
morphisms associated with altered cytokine
responses in vitro may modify age of onset of psoria-
sis. They also provide further evidence that patients
with early and late onset psoriasis differ in their gen-
etic background. Key words: cytokine polymorphism/
in¯ammation/skin. J Invest Dermatol 118:155±163, 2002
P
soriasis is a complex in¯ammatory skin disease that
involves keratinocyte hyperproliferation and aberrant
differentiation, dermal angiogenesis, and a mixed
leukocytic in®ltrate composed of activated T cells,
neutrophils, and mast cells. The tissue alterations seen in
psoriasis are thought to be driven by an exaggerated production of
pro-in¯ammatory cytokines, such as tumor necrosis factor (TNF)-
a, interferon-g, interleukin (IL)-1b, IL-8, and IL-12 (reviewed in
Bos and De Rie, 1999). On the other hand, there is evidence that
anti-in¯ammatory factors, such as IL-10 and the IL-1 receptor
antagonist (IL-1Ra), are relatively decreased and their levels
insuf®cient to compensate for the increased formation of pro-
in¯ammatory mediators (Gruaz-Chatellard et al, 1991; Bigler et al,
1992; Nickoloff et al, 1994; Asadullah et al, 1998). The key role of a
disturbed cytokine balance in psoriasis is supported by the clinical
response to exogenous administration of IL-10 (Reich et al, 2001;
Asadullah et al, 2001) and anti-TNF-a therapy (Mease et al, 2000;
Ogilvie et al, 2001).
The mechanisms underlying aberrant cytokine expression in
psoriasis remain to be de®ned. Notably, abnormal cytokine levels
are detectable not only in cutaneous lesions, but also in nonlesional
skin, sera, isolated peripheral blood mononuclear cells, and the
synovia of affected joints (Uyemura et al, 1993; Bonifati et al, 1994;
Asadullah et al, 1998; Austin et al, 1999). Hence, discordant
cytokine production appears to be a general phenomenon in
psoriatic patients, suggesting a genetic predisposition to over-
production of pro-in¯ammatory and/or impaired responsiveness to
anti-in¯ammatory signals.
Genetic factors are likely to play a fundamental part in the
manifestation of psoriasis. The results of family, twin, and human
leukocyte antigen (HLA) allotype studies as well as genome-wide
scans in affected families all point to a genetic basis for psoriasis
susceptibility, which is complex and likely to re¯ect the action of a
number of genes (reviewed in Capon et al, 2000). One of the most
consistent observations is the association with genes encoded on the
short arm of chromosome 6 within the major histocompatibility
complex region. There is also evidence that disease subtypes within
psoriasis may differ in their genetic background. Patients with early
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onset disease (before the age of 40 y) are predominantly carriers of
HLA-Cw6, -B57, and -DR7, and often have a positive family
history, whereas patients with late onset disease (age at onset
> 40 y) often have sporadic disease, and the association with HLA
alleles is weaker (reviewed in Henseler, 1998).
During recent years it has become apparent that many genes
encoding important regulatory cytokines are subject to genetic
polymorphism in humans, and that variant cytokine alleles can be
markers of enhanced susceptibility to immune-mediated diseases
(Bidwell et al, 1999). The gene encoding TNF-a (TNFA; OMIM:
*191160) is located centromerically to HLA-B within the major
histocompatibility complex class III region (further information on
OMIM *191160 is available under http://www.3.ncbi.nlm.nih.-
gov/Omim/searchomim.html). It contains a number of poly-
morphisms, including ®ve microsatellites and several single
nucleotide polymorphisms particularly in the promoter region. In
Caucasian populations, the most common polymorphisms are two
G to A transitions in the promoter at positions ±238 (D'Alfonso and
Richiardi, 1994) and ±308 (Wilson et al, 1992). Current data
obtained from reporter gene assays and cell culture experiments
suggest that these polymorphisms affect cytokine production;
however, their exact functional consequence is still controversial
(Pociot et al, 1995; Kroeger et al, 1997, 2000; Wilson et al, 1997;
Kaluza et al, 2000).
Because of its location within the major histocompatibility
complex region, the presence of polymorphisms that are likely to
in¯uence gene expression, and the key role of aberrant TNF-a
expression in psoriasis, TNFA has been considered a candidate gene
in psoriasis. We and colleagues have observed an association of
allele 2 of the TNFA±238 polymorphism (A at ±238) with the
disease in European patients (Arias et al, 1997; Hohler et al, 1997;
Reich et al, 1999), although this was not con®rmed in another
report (Jacob et al, 1999). In concert, the reported ®ndings suggest a
considerable variation in the distribution of TNFA polymorphisms
among psoriasis subgroups that might be de®ned by gender, age at
onset, and a positive or negative family history. Until now,
however, this has not been systematically investigated.
Consequently, this study addressed the role of TNFA promoter
polymorphisms in psoriasis subgroups. In addition, we re-investi-
gated the functional impact of these polymorphisms on the
production of TNF-a in response to pro-in¯ammatory and anti-
in¯ammatory stimuli in vitro. In light of the important contribution
of the IL-1 system to the psoriatic in¯ammatory process (Prens et al,
1996; Wei et al, 1999; Schon et al, 2001), we extended our
investigation to polymorphisms in the genes encoding IL-1b (IL1B;
OMIM: *147720) and its natural antagonist, IL-1Ra (IL1RN;
OMIM: *147679).
MATERIALS AND METHODS
Patients Unrelated German Caucasian patients with psoriasis (n = 231
cases) were consecutively enrolled from the psoriasis clinic at the
Department of Dermatology, University Hospital GoÈttingen (Germany),
which longitudinally follows such patients in Southern Lower Saxony.
All patients were seen by an experienced dermatologist (K.R.) and
recruited if they had an unequivocal clinical diagnosis of psoriasis
vulgaris. Patients with psoriasis were considered to have ``early onset
disease'' if disease onset was before 40 y of age and ``late onset disease'' if
age at onset was > 40 y according to the classi®cation of Henseler and
Christophers (1985). Healthy unrelated German Caucasians (n = 345)
recruited from the blood donor registry of the Department of
Transfusion Medicine, University Hospital GoÈttingen, and from among
local health care personnel served as controls. Health status was
determined by skin examination and a record of the personal and familial
medical history. Characteristics of the study participants are shown in
Table I. None of the control subjects had a positive family history for
psoriasis. The study was approved by the Institutional Review Board of
the Medical Faculty of the University of GoÈttingen, and informed
consent was obtained from all participants.
Preparation of genomic DNA Peripheral blood (10 ml) was collected
in sterile tubes containing ethylenediamine tetraacetic acid as an anti-
coagulant. Extraction of DNA from buffy coats was performed by a
salting out procedure. Brie¯y, lymphocytes were collected at 400 3 g
and 4°C, and lyzed in 50 mM Tris±HCl (pH 8.0), 20 mM
ethylenediamine tetraacetic acid (pH 8.0), and 2% sodium dodecyl
sulfate. Protein was digested with Proteinase K (6 h at 56°C) and
pelleted with 6 M NaCl following centrifugation at 5000 3 g for
20 min. DNA was precipitated with 1.5 3 vol. 100% ethanol. DNA
yields were between 0.1 and 1 mg per ml.
IL1RN VNTR polymorphism The fragment of the IL1RN gene
containing variable numbers of an identical tandem repeat of 86 bp was
ampli®ed by polymerase chain reaction (PCR) with the primers 5¢-
CTCAGCAACACTCCTAT-3¢ (sense) and 5¢-TCCTGGTCTGCAGG-
TAA-3¢ (anti-sense) as previously described (Tarlow et al, 1993).
Ampli®cation was performed with 2 ml primers (10 pmol per ml;
Eurogentec, Seraing, Belgium), 0.9 ml MgCl2 (50 mM), 3 ml
deoxyribonucleoside triphosphates (3.75 mM; Amresco, Solon, Ohio,
USA), 0.2 mL TaqPol (5 U per ml; Eurogentec), 3 ml 10 3 Taq buffer
(Eurogentec), and 200±600 ng genomic DNA in a ®nal volume of
30 ml. PCR conditions were as follows: initial denaturation at 94°C for
4 min, followed by 32 cycles of denaturation at 94°C for 1 min,
annealing at 50°C for 1 min and elongation at 72°C for 1 min with a
®nal elongation at 72°C for 10 min and cooling down to 4°C. PCR
products were analyzed by electrophoresis on a 2% agarose gel stained
with ethidium bromide. Alleles 1±5 (IL1RN*1±IL1RN*5) were
detected according to their size relative to a 100 bp DNA ladder (Gibco
BLR, Eggenstein, Germany) as published (Mans®eld et al, 1994): allele 1
(four repeats) 410 bp; allele 2 (two repeats) 240 bp; allele 3 (®ve repeats)
Table I. Characteristics of study participants
Early onset psoriasisa Late onset psoriasis Healthy control
Total number of individuals 156 75 345
Sex
female 51 (33%) 29 (39%) 163 (47%)
male 105 (67%) 46 (61%) 182 (53%)
Age (y)
Mean (SD) 41.5 (14.2) 61.1 (11.0) 36.1 (12.3)
Median (range) 39.5 (11±92) 60.0 (42±86) 33.0 (18±77)
Age of onset of symptoms (y)
Mean (SD) 23.3 (9.5) 53.3 (10.5)
Median (range) 24.0 (3±39) 52.0 (40±85)
Disease duration (y)
Mean (SD) 18.7 (16.2) 6.0 (6.7)
Median (range) 16.0 (1±71) 3.0 (1±23)
Positive family historyb 82 (52%) 13 (18%) 0 (0%)
aEarly onset = age at onset < 40 y; late onset = age at onset >40 y.
bOne or more ®rst- or second-degree relative with psoriasis.
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500 bp; allele 4 (three repeats) 325 bp. Allele 5 (six repeats; 595 bp) was
not observed in the study population.
IL1B±511 and +3953 polymorphisms The region containing the
biallelic polymorphism de®ned by a C to T transition at position ±511 of
the IL1B promoter was ampli®ed by PCR using the primers 5¢-TGG-
CATTGATCTGGTTCATC-3¢ (sense) and 5¢-GTTTAGGAATCTTC-
CCACTT-3¢ (anti-sense) as described (Mans®eld et al, 1994). The PCR
product was digested overnight at 37°C in a total volume of 20 ml
containing 0.5 ml AvaI (10 U per ml) and 2 mL AvaI buffer (both from
New England Biolab, Schwalbach/Taunus, Germany) and visualized by
electrophoresis on a 2.5% agarose gel stained with 0.1% ethidium
bromide. As described (di Giovine et al, 1992), digestion of IL1B±511
allele 1 (IL1B±511*1; C at ±511) results in two fragments of 190 and
114 bp, respectively, whereas IL1B±511*2 (IL1B±511*2; T at ±511) is
not digested (304 bp). The primers 5¢-GTTGTCATCAGACTTT-
GACC-3¢ (sense) and 5¢-TTCAGTTCATATGGACCA-GA-3¢ (anti-
sense) were used to amplify the polymorphic region at position +3953 in
exon 5 of the IL1B gene (Bioque et al, 1995) de®ned by a silent T to C
transition (Pociot et al, 1994). The PCR product was subjected to
digestion by TaqI (New England Biolab) at 65°C overnight in a reaction
volume of 20 ml containing 0.5 ml TaqI (20 U per ml) and 2 ml TaqI
buffer (New England Biolab). The 249 bp PCR product either remains
intact (C at +3953; allele 2) or is cut in two smaller fragments of 135 bp
and 114 bp, respectively (T at +3953; allele 1) (Bioque et al, 1995).
Fragments were visualized as above. PCR conditions for ampli®cation of
the IL1B polymorphic regions were as described for IL1RN with the
exception that an annealing temperature of 57°C was used.
TNFA promoter polymorphisms The single nucleotide
polymorphisms at positions ±238 and ±308 of the TNFA promoter were
analyzed by PCR±restriction fragment length polymorphism and allele-
speci®c PCR, respectively, as previously described (Couchane et al,
1997; Day et al, 1998). Variant alleles carrying an A are denoted as allele
2 (TNFA±238*2 and TNFA±308*2, respectively).
Cell culture For functional studies, peripheral blood mononuclear cells
(PBMC) were isolated by density gradient centrifugation of heparinized
whole blood with Ficoll-Paque (Pharmacia, Freiburg, Germany). All
donors were free from clinical disease and did not use medication that
might have affected cytokine production. Plasma levels of cortisol and
estradiol were determined at the time of blood sampling. PBMC were
cultured for 48 h in Iscove's medium supplemented with 10% fetal
bovine serum (lot no. 371S), 100 U penicillin G per ml, and 100 mg
streptomycin per ml (all purchased from Biochrom KG, Berlin,
Germany) at 1 3 106 cells per ml in 24-well ¯at bottom culture plates
(Greiner, Solingen, Germany) in a 37°C humidi®ed 5% CO2
atmosphere. Cells were stimulated with either 1 mg lipopolysaccharide
(LPS) per ml (Sigma, Deisenhofen, Germany), LPS together with 5 U
recombinant human IL-10 per ml (Peprotech, London, U.K.), or left
untreated (medium control). Optimal concentrations of stimuli were
determined in preliminary experiments. Supernatants were harvested at
2, 4, 8, 24, and 48 h to investigate the kinetics of cytokine release
(n = 5 healthy donors). In subsequent experiments, PBMC were isolated
from 36 individuals (27 females, nine males; 25±55 y) selected from the
healthy control group by quota sampling according to their TNFA and
IL1 genotype, and supernatants were harvested at 8 h and 24 h. Protein
levels of TNF-a, IL-1b, and IL-1RA were determined by enzyme-
linked immunosorbent assay according to the manufacturer's instructions
(Coulter Immunotech, Marseille, France) (sensitivity TNF-a, 1 pg per
ml; IL-1b, 15 pg per ml; IL-1Ra, 30 pg per ml).
Statistical analysis Results of cytokine measurements are given as
mean 6 SEM. Mean values obtained in different groups de®ned by
carriage or noncarriage of cytokine gene polymorphisms were compared
exploratorily by the asymptotic two-sided unpaired t test with
homogeneous variances (prism 2.01; GraphPad, San Diego, CA). IL-1Ra
to IL-1b ratios were likewise compared between these groups
exploratorily by the asymptotic two-sided Mann±Whitney U test (prism
2.01). In the case of kinetic experiments with different stimuli, IL-1Ra/
IL-1b ratios were evaluated globally by Kruskal±Wallis ANOVA (prism
2.01). Notable differences between the stimuli were then compared
exploratorily by the Mann±Whitney U test. Association between in vitro
production of IL-1b and IL-1Ra and plasma levels of estradiol or cortisol
was estimated by Spearman's correlation coef®cient (prism 2.01).
The frequency of genotypes, including at least one allele 2 at TNFA±
238 and of the *1/1 genotype at IL1B±511 were compared between
subgroups by Fisher's two-sided exact test. Odds ratios (OR) and exact
95% con®dence intervals (CI) were computed using StatXact (Version
3.1, Cytel Software Corporation, Cambridge, MA). To correct for
multiple testing, the following hierarchical test strategy was adhered to:
1 The genotype frequencies of cases and controls were compared at
TNFA±238 and IL1B±511 at a global signi®cance level of 5%. The
respective nominal p-values were adjusted according to Bonferroni for
conducting two tests.
2 If signi®cant at any of the two loci, genotype frequencies in the
groups of cases with early onset of disease, late onset of disease, and
controls were compared pairwise. At TNFA±238, a signi®cantly higher
frequency of allele 2 in early onset patients over controls has been
reported previously (Arias et al, 1997; Hohler et al, 1997; Reich et al,
1999). Hence, only the comparison of this pair was tested for signi®-
cance, the other pairs (late onset cases vs controls and early onset vs late
onset cases) were tested merely exploratory. At IL1B±511, however, all
three pairs were tested for signi®cance, and the nominal p-values were
adjusted for performing three tests according to Shaffer (1986).
3 If signi®cantly different frequencies were detected between any of
these pairs, the same groups were tested separately within each gender
and within patients with a positive and a negative family history. To
correct for the testing of these two factors, nominal p-values were again
adjusted according to Bonferroni. As two subgroups were tested for each
factor, nominal p-values were further adjusted for the performance of
two tests according to Bonferroni±Holm (Holm, 1979). Adjusted p-
values < 0.05 were considered signi®cant evidence of association.
To evaluate deviation from the Hardy±Weinberg equilibrium, we
exploratorily compared observed and expected frequencies by an exact
c2-test for goodness of ®t in cases and controls.
RESULTS
TNFA and IL1B promoter polymorphisms affect cytokine
production in vitro The effects of IL-10 on the LPS-induced
production of TNF-a, IL-1b, and IL-1Ra were studied during
48 h culture of PBMC obtained from ®ve healthy donors (Fig 1).
As expected, LPS upregulated the release of TNF-a and IL-1b
protein, with peak concentrations detectable at 8 h, and IL-10
strongly decreased TNF-a and IL-1b secretion at all time-points
(Fig 1a, b). Induction of IL-1Ra in response to LPS reached a
maximum at 24 h. In accordance with earlier results (Jenkins et al,
1994), addition of IL-10 slightly enhanced IL-1Ra at 4 h, and
tended to decrease IL-1Ra levels at 24 h and 48 h (Fig 1c). A likely
explanation is that IL-10 directly enhances IL-1Ra, but inhibits
LPS-induced TNF-a, which acts as a strong inducer of IL-1Ra
(Danis et al, 1995). The differential effects of IL-10 on the secretion
of IL-1Ra and IL-1b in response to LPS resulted in a notable
change of the balance between these two cytokines. At 24 h the
molar ratio of secreted IL-1Ra to IL-1b was approximately 2 in
response to LPS alone, compared with approximately 25 in
response to LPS and IL-10 (exploratory p = 0.0079; Fig 1d).
There were considerable interindividual variations in the
cytokine response to LPS and IL-10. In order to investigate
whether TNFA and IL1 gene polymorphisms in¯uence cytokine
production in our system, 36 individuals from the control group
were selected for functional studies by quota sampling according to
their IL1 and TNFA genotypes. PBMC derived from carriers of at
least one TNFA±238 allele 2 were found to produce more TNF-a
in response to LPS than PBMC of carriers of two wild-type alleles
[3613 6 590 vs 2095 6 274 pg per 106 cells per 8 h (all values
mean 6 SEM); exploratory p = 0.0129]. Furthermore, when cells
were additionally treated with IL-10, secreted levels of TNF-a in
cultures derived from carriers of promoter polymorphisms
remained above those detectable in cultures derived from
homozygous wild-type individuals (Fig 2a); however, when the
inhibitory effect of IL-10 was calculated as percent inhibition of
LPS-induced TNF-a secretion on an individual basis, similar values
were found in the three genotypic groups (wild-type: 85 6 2%,
TNFA±308*2 carriers: 81 6 4%, TNFA±238*2 carriers:
86 6 3%), suggesting that the difference in LPS/IL-10-treated
cultures was mainly due to a differential response towards LPS.
PBMC obtained from homozygous carriers of IL1B±511 allele 1
produced more IL-1Ra than PBMC obtained from individuals
carrying at least one IL1B±511 allele 2. This effect was observed in
cultures stimulated with LPS alone, and was more pronounced in
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cultures additionally treated with IL-10 (Fig 2b). In response to
LPS/IL-10, the mean production of IL-1Ra was 9618 6 1493 pg
per 106 cells per 24 h in cultures of IL1B±511*1/1 homozygous
donors compared with 4070 6 704 pg per 106 cells per 24 h in
cultures of carriers of IL1B±511*2 (exploratory p = 0.0072). The
amounts of IL-1b (Fig 2b) and TNF-a (not shown) secreted in
response to LPS and LPS/IL-10 were similar in these two groups.
Calculation of the ratio of IL-1Ra/IL-1b detectable in supernatants
of these cultures further underlined the difference in the biologic
response. The mean ratio in LPS/IL-10-treated cultures derived
from carriers of IL1B±511*2 at 24 h was 16 6 5 compared with
29 6 5 in cultures derived from homozygous carriers of IL1B±
511*1 (exploratory p = 0.0439; Fig 2c), indicating that the latter
were more sensitive to the anti-in¯ammatory effects of IL-10. The
effect of the IL1B±511 polymorphism on the IL-Ra to IL-1b ratio
was independent of the presence of IL1B + 3953 or IL1RN
polymorphisms, and no other associations between carriage of IL1B
or IL1RN polymorphisms and secretion levels of IL-1b or IL-1Ra
were observed. In addition, there was no difference between male
and female donors (exploratory p > 0.05), and no correlation
between ex vivo cytokine production and plasma levels of estradiol
or cortisol determined at the time of blood sampling.
Association between TNFA±238 promoter polymorphism
and early onset psoriasis; effect of gender and family
history The absolute and relative frequencies of TNFA
promoter genotypes are shown in Table II. No signi®cant
deviation from Hardy±Weinberg equilibrium was detected at the
TNFA±238 locus in either cases or controls (nominal p > 0.05). In
accordance with earlier studies (Hohler et al, 1997), genotype
frequencies at the TNFA±308 locus deviated from Hardy±
Weinberg equilibrium in controls (nominal p = 0.0480) but not
in cases (nominal p > 0.05).
As expected from previous results, carriers of the TNFA±238*2
allele were signi®cantly more common among patients with
psoriasis than among healthy controls [23% vs 8%; OR = 3.24,
95% CI (1.94±5.49); padjusted = 3 3 10
±6]. Analyzing subgroups of
psoriasis patients separately (Table III), a signi®cantly higher
frequency of TNFA±238*2 allele carriers was detected in patients
with early onset of disease (27%) as compared with healthy controls
[8%, OR = 4.02 (2.31±7.00); padjusted = 3 3 10
±7]. Additionally,
when testing this effect within the gender groups, there was
evidence for gender-speci®c differences in the role of TNFA±
238*2 as a risk factor for psoriasis. Among male patients with early
onset of disease, TNFA±238*2 was signi®cantly over-represented
as compared with male controls [32% vs 7%; OR = 6.78 (3.18±
15.15); padjusted = 2 3 10
±7], but was similarly distributed among
female patients with early disease onset and female controls [16% vs
10%; OR = 1.60 (0.56±4.23); padjusted = 0.7888]. In contrast,
exploratory analysis revealed no enhancement of TNFA±238*2
in patients with late onset psoriasis [17% vs 8% in controls,
OR = 1.87 (0.80±4.10); exploratory p = 0.1255] (Table III).
As patients with early onset of psoriasis often have a positive
family history (Henseler and Christophers, 1985), we also inves-
tigated whether the higher frequency of TNFA±238*2 in early
onset patients might be found in patients with either sporadic or
familial disease. Carriage of TNFA±238*2 was signi®cantly more
common among early onset patients with a positive family history
(33%) than among controls [8%, OR = 5.35 (2.90±10.12),
padjusted = 7´10
±7]. Notably, however, TNFA±238*2 was still
over-represented in early onset patients with sporadic psoriasis
(20%) as compared with healthy controls [8%, OR = 2.77 (1.29±
5.71), padjusted = 0.0218].
Association between IL1B±511 promoter polymorphism
and late onset psoriasis Absolute and relative frequencies of
genotypes at the investigated IL1 loci are given in Table II.
Genotype frequencies of IL1B and IL1RN polymorphisms in the
healthy control group were similar to those reported for healthy
European Caucasians in other studies (Bioque et al, 1995; Hacker et
al, 1998; Schrijver et al, 1999; El-Omar et al, 2000), and no
signi®cant deviation from Hardy±Weinberg equilibrium was
detected at any of the IL1 loci within either cases or controls (all
nominal p > 0.05). As can be seen, homozygous carriers of allele 1
of the IL1B±511 promoter polymorphism (IL1B±511*1/1) were
signi®cantly more common among patients with psoriasis than
among healthy controls [55% vs 44%; OR 1.54 (1.09±2.19);
padjusted = 0.0268]. When patients with early and late disease onset
were analyzed separately (Table IV), a signi®cantly higher
frequency of the IL1B±511*1/1 genotype was detected among
patients with late disease onset as compared with healthy controls
[61% vs 44%; OR = 2.04 (1.19±3.53); padjusted = 0.0419]. In
contrast, frequencies in early onset patients (51%) were not
signi®cantly different from either controls [44%, OR = 1.35
(0.91±2.01), padjusted = 0.2302] or late onset patients [61%,
OR = 1.51 (0.83±2.76), padjusted = 0.2959]. Comparing late
onset patients with controls separately within males (63% vs 41%)
and females (59% vs 47%), the IL1B±511*1/1 genotype frequencies
did not signi®cantly differ [OR = 2.43 (1.19±5.07) and 1.62 (0.68±
3.97); padjusted = 0.2588 and 0.9890, respectively]. Likewise, no
signi®cant differences were detected when genotype frequencies of
late onset patients with positive (77%) or negative family history
Figure 1. Effects of IL-10 on the LPS-
induced release of TNF-a, IL-1b, and IL-
1Ra. PBMC were isolated from ®ve healthy
donors and cultured with LPS alone (1 mg per ml)
or in combination with recombinant human IL-
10 (5 U per ml) for 48 h. The amount of TNF-a
(a), IL-1b (b), and IL-1Ra protein (c) present in
the supernatants at the given time-points was
determined by enzyme-linked immunosorbent
assay. Absolute values for cytokine levels are given
in pg per ml with 1 ml containing 1 3 106 cells.
(d) Molar ratios of IL-1Ra to IL-1b were
calculated for individual culture supernatants at the
given time-points. Note the different scaling of
the right (LPS) and left (LPS + IL-10) y-axis.
Symbols and bars represent mean 6 SEM.
**Exploratory p < 0.01 (Mann±Whitney U test
after Kruskal±Wallis ANOVA with exploratory
p < 0.0001).
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(58%) were compared with healthy controls [44%, OR = 4.28
(1.07±24.54) and 1.80 (0.99±3.21), padjusted = 0.4251 and 0.3804,
respectively].
DISCUSSION
Overexpression of pro-in¯ammatory cytokines such as TNF-a
(Reich et al, 2001) and IL-1b (Debets et al, 1995, 1997) compared
with a relative de®ciency of anti-in¯ammatory factors is a central
phenomenon in psoriasis and considered to play an important role
in the initiation, maintenance, and reoccurrence of psoriatic lesions.
In the present study, we con®rm and extend previous observations
that aberrant cytokine production in psoriasis may at least partly be
determined by genetic factors, and provide a new concept for the
possible role of cytokine gene polymorphisms in modifying disease
onset.
First, our current data support earlier ®ndings that carriage of
allele 2 of the TNFA±238 promoter polymorphism (A at ± 238) is
associated with psoriasis (Arias et al, 1997; Hohler et al, 1997; Reich
et al, 1999). As TNFA±238*2 was found to correlate with
enhanced production of TNF-a in LPS-stimulated PBMC,
carriage of this allele may contribute to the increased formation
of TNF-a observed in psoriasis.
Overproduction of pro-in¯ammatory mediators may also result
from an impaired responsiveness to anti-in¯ammatory signals. In an
earlier investigation we obtained evidence that the capacity of
exogenous IL-10 to reduce cutaneous TNF-a expression in
psoriatic patients is decreased in carriers of variant TNFA alleles
as compared with carriers of two wild-type alleles (Reich et al,
2001). Here, we found that levels of TNF-a in LPS-stimulated
PBMC additionally treated with IL-10 were higher in cultures
derived from carriers than in those derived from noncarriers of
promoter variants, suggesting that these polymorphisms may, in
fact, interfere with the control of TNF-a by IL-10. The molecular
mechanisms by which TNFA promoter polymorphisms may
in¯uence the regulation of TNF-a production remain to be
determined. Notably, TNF-a secretion in response to LPS is
predominantly regulated at the transcriptional level (Raabe et al,
1998). The TNFA±238 polymorphism lies in a putative regulatory
box of the TNFA gene (D'Alfonso and Richiardi, 1994), and a
repressor site has been localized to a 25 bp interval between
positions ± 254 and ± 230 in the promoter (Fong et al, 1995).
Second, analyzing further the distribution of TNFA polymorph-
isms in psoriasis subgroups, we con®rmed our earlier ®nding that
TNFA±238*2 is a risk factor for psoriasis in males (Reich et al,
1999). Within males, carriage of TNFA±238*2 was associated with
early onset disease; the chance of carrying this allele was
approximately 6-fold higher in male patients developing psoriasis
before the age of 40 y than in healthy male controls. It has
previously been reported that the distribution of age at onset of
Figure 2. TNFA and IL1B promoter polymorphisms in¯uence
the cytokine release from PBMC. PBMC were isolated from healthy
donors (n = 36) and stimulated as described in Fig 1. Donors were
selected by quota sampling according to their TNFA and IL1 genotypes.
(a) TNF-a protein levels were measured by enzyme-linked
immunosorbent assay in culture supernatants at 8 h. Values obtained in
cultures derived from carriers of variant TNFA alleles after stimulation
with LPS (left y-axis) or LPS in combination with IL-10 (right y-axis)
were compared with the corresponding values obtained in cultures
derived from carriers of two wild-type alleles (TNFAwt). *Exploratory
p < 0.05 (t test). (b) Protein levels of IL-1Ra (left y-axis) and IL-1b
(right y-axis) in culture supernatants at 24 h. Carriers of two copies of
IL1B±511*1 (± 511*1/1 homozygous genotype) produced more IL-1Ra
than carriers of at least one IL1B±511*2 allele (± 511*2+). The
difference between these groups was present in cultures treated with LPS
alone and in cultures treated with LPS and IL-10. **Exploratory
p < 0.01 (t test). (c) The ratio of secreted IL-1Ra to IL-1b at 24 h was
higher in ± 511*1/1 homozygous individuals than in carriers of ± 511*2
(*exploratory p < 0.05, Mann±Whitney U test). Bars and error bars
represent mean 6 SEM. n, number of individuals investigated in each
group.
Table II. Frequencies of TNFA and IL1 genotypes in the
investigated groups
Locus Genotype
Control
(n = 345)
n (%)
Psoriasis
(n = 231)
n (%)
TNFA±238 1/1 316 (91.6) 178 (77.1)
1/2 29 (8.4) 52 (22.5)a
2/2 0 1 (0.4)
TNFA±308 1/1 238 (69.0) 178 (77.1)
1/2 103 (29.9) 53 (22.9)
2/2 4 (1.2) 0
IL1B±511 1/1 151 (43.8) 126 (54.5)b
1/2 162 (47.0) 87 (37.7)
2/2 32 (9.3) 18 (7.8)
IL1B+3953 1/1 189 (54.8) 127 (55.0)
1/2 132 (38.3) 86 (37.2)
2/2 24 (7.0) 18 (7.8)
IL1RN 1/1 172 (49.9) 117 (50.7)
1/2 127 (36.8) 85 (36.8)
1/3,4 14 (4.1) 9 (3.9)
2/2 30 (8.7) 17 (7.4)
2/3,4 2 (0.6) 3 (1.3)
aOdds ratio = 3.24, 95% con®dence interval = 1.94±5.49, nominal p-value =
1 3 10±6, adjusted p-value = 3 3 10±6 TNF±238*1/2 and *2/2 psoriasis vs
control.
bOdds ratio = 1.54, 95% con®dence interval = 1.09±2.19, nominal p-value =
0.0135, adjusted p-value = 0.0268 IL1B±511 *1/1 psoriasis vs control.
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psoriasis can be explained by two underlying distributions, thus
rendering two subtypes of the disease (Henseler and Christophers,
1985). Within males, the early type shows a peak at about 20 y, the
late type at about 60 y; however, there is considerable overlap of
the graphs for ages between 25 y and 50 y (Henseler and
Christophers, 1985). Hence, it might be interesting to single out
male patients with an unambiguous early disease onset (before age
of 25 y) and those with a clear late onset (after age of 50 y).
Figure 3 shows an exploratory comparison of the frequencies of
TNFA±238*2 carriers in each of these groups. It can be seen that
the overrepresentation of TNFA±238*2 carriers in male psoriasis
patients is mainly due to the high frequency in the group of patients
with an onset earlier than 25 y. Speci®cally, almost half of the male
psoriasis patients with this early onset carry the respective allele
(47%). In contrast, male patients with a medium age at onset
(between 25 y and 49 y) do not differ notably from those with a
late onset (19% and 16%, respectively), indicating that TNFA±
238*2 is a marker of very early onset psoriasis in males.
Carriage of TNFA±238*2 was more common among early onset
patients with familial as well as sporadic disease compared with
healthy controls. Therefore, the effect of TNFA±238*2 seems to be
partially independent of the family history. It remains to be further
investigated why TNFA±238*2 seems to play a decisive part in
psoriasis susceptibility only in males. Interestingly, gender-speci®c
differences in the role of variant TNFA alleles as a risk factor for
mucocutaneous leishmaniasis and extensive forms of ulcerative
colitis have also been reported (Cabrera et al, 1995; Koss et al,
2000). In concert with the results described here, these ®ndings
Table III. TNFA±238 genotype frequencies in psoriasis
Genotype
Comparison OR (95% C1)a p (nom) p (adj)
1/2 or 2/2
n (%)
1/1
n (%)
Age of onset
Psoriasis early 42 (27) 114 (73) eo cases vs controlsb 4.02 (2.31±7.00) 1 3 10±7 3 3 107
late 11 (15) 64 (85) lo cases vs controls 1.87 (0.80±4.10) 0.1255
Control 29 (8) 316 (92) eo vs lo cases 2.14 (1.00±4.93) 0.0449
Gender
Early onset males 34 (32) 71 (68) eo male cases vs male controls 6.78 (3.18±15.15) 2 3 10±8 2 3 10±7
females 8 (16) 43 (84) eo female cases vs female controls 1.60 (0.56±4.23) 0.3221 0.7888
Late onset males 6 (13) 40 (87) lo male cases vs male controls 2.13 (0.61±6.55) 0.2153
females 5 (17) 24 (83) lo female cases vs female controls 1.79 (0.47±5.68) 0.3390
Control males 12 (7) 170 (93) eo vs lo male cases 3.19 (1.18±10.05) 0.0157
females 17 (10) 146 (90) eo vs lo female cases 0.89 (0.23±3.88) 1.0000
Family history
Early onset positive 27 (33) 55 (67) eo positive cases vs controls 5.35 (2.80±10.12) 9 3 10±8 7 3 10±7
negative 15 (20) 59 (80) eo negative cases vs controls 2.77 (1.29±5.71) 0.0055 0.0218
Late onset positive 2 (15) 11 (84) lo positive cases vs controls 1.98 (0.20±9.73) 0.3125
negative 9 (15) 53 (86) lo negative cases vs controls 1.85 (0.73±4.30) 0.1521
Control 29 (8) 316 (92) eo vs lo positive cases
eo vs lo negative cases
2.70 (0.53±26.54)
1.50 (0.56±4.21)
0.3317
0.4990
aOR, odds ratio; CI, con®dence interval; p (nom), two-sided nominal p-value; p (adj), two-sided adjusted p-value
beo, early onset; lo, late onset
Table IV. IL1B-511 genotype frequencies in psoriasis
Genotype
Comparison OR (95% C1)a p (nom) p (adj)
1/1
(n%)
1/2 or 2/2
(n%)
Age of onset
Psoriasis early 80 (51) 76 (49) eo cases vs controlsb 1.35 (0.91±2.01) 0.1226 0.2302
late 46 (61) 29 (39) lo cases vs controls 2.04 (1.19±3.53) 0.0071 0.0419
Control 151 (44) 194 (56) eo vs lo cases 1.51 (0.83-2.76) 0.16090 2959
Gender
Early onset males 54 (51) 51 (49) eo male cases vs male controls 1.51 (0.91±2.52) 0.1095
females 26 (51) 25 (49) eo female cases vs female controls 1.19 (0.60±2.35) 0.6317
Late onset males 29 (63) 17 (37) lo male cases vs male controls 2.43 (1.19±5.07) 0.0124 0.2588
females 17 (59) 12 (41) lo female cases vs female controls 1.62 (0.68±3.97) 0.3135 0.9890
Control males 75 (41) 107 (59) eo vs lo male cases 1.61 (0.75±3.52) 0.2158
females 76 (47) 87 (53) eo vs lo female cases 1.36 (0.49±3.81) 0.6416
Family history
Early onset positive 40 (49) 42 (51) eo positive cases vs controls 1.22 (0.73±2.04) 0.4590
negative 40 (54) 34 (46) eo negative cases vs controls 1.51 (0.89±2.59) 0.1230
Late onset positive 10 (77) 3 (23) lo positive cases vs controls 4.28 (1.07±24.54) 0.0228 0.4251
negative 36 (58) 26 (42) lo negative cases vs controls 1.80 (0.99±3.21) 0.0391 0.3804
Control 151 (44) 194 (56) lo vs eo positive cases
lo vs eo negative cases
3.50 (0.81±20.96)
1.18 (0.56±2.46)
0.0759
0.7293
aOR, odds ratio; Cl, con®dence interval; p (nom), two-sided nominal p value; p (adj), two-sided adjusted p value.
beo, early onset; lo, late onset.
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may indicate a gender-speci®c modulation of the contribution of
TNFA polymorphisms to the development of infectious and
chronic in¯ammatory diseases.
Third, we present ®rst evidence that polymorphisms of the IL1
gene, already implicated in a variety of chronic in¯ammatory and
autoimmune conditions, including in¯ammatory bowel disease
(Mans®eld et al, 1994; Bioque et al, 1995), are also part of the
genetic components involved in psoriasis. The genes encoding IL-1
and IL-1Ra are clustered together on chromosome 2q14. In the
IL1B gene there are two base-exchange polymorphisms at positions
± 511 in the promoter region (di Giovine et al, 1992) and at
position + 3953 in the ®fth exon (Pociot et al, 1994), and the
IL1RN gene has a penta-allelic polymorphic site in intron 2
containing variable numbers of an 86 bp tandem repeat sequence
(Tarlow et al, 1993). Whereas data on the functional consequences
of these polymorphisms are partly contradictory (Pociot et al, 1992;
Santilla et al, 1998), recent in vitro and in vivo studies suggest that the
production of IL-1b and IL-1Ra is co-ordinately regulated by IL1B
and IL1RN alleles (Hurme and Santtila, 1998; Santilla et al, 1998),
possibly through the existence of ®xed haplotypes at these loci and
the presence of shared regulatory elements. This interaction may
re¯ect the biologic role of the IL-1 system, which is determined by
the balance between IL-1 agonists and antagonists (reviewed in
Dinarello, 2000).
We found in our study groups that carriage of the IL1B±511*1/1
genotype is signi®cantly more common in patients with late onset,
but not in those with early onset psoriasis as compared with healthy
controls. Tarlow et al (1997) reported a decreased frequency of
IL1RN allele 2 in patients with late onset psoriasis (age of onset
> 40 y), but the ®nding was only of borderline signi®cance, and
polymorphisms of the IL1B gene were not investigated. In light of
our new ®nding of a signi®cant overrepresentation of the IL1B±
511*1/1 genotype among patients with late onset psoriasis, and
given the strong association between IL1B±511 allele 1 and IL1RN
allele 1 (Hurme and Santtila, 1998; El-Omar et al, 2000), the
observation by Tarlow et al (1997) may re¯ect linkage disequilib-
rium between IL1B±511 and ILRN alleles. Interestingly, on a
functional level, we obtained ®rst evidence that the IL-1B±511
polymorphism in¯uences the anti-in¯ammatory effects of IL-10.
Thus, the ratio of secreted IL-1Ra to IL-1b in response to LPS and
additional treatment with IL-10 was greater in PBMC cultures
derived from homozygous carriers of IL1B±511*1 (CC genotype)
than in those derived from carriers of at least one IL1B±511*2 allele
(CT or TT genotype).
Taken together, these data indicate that promoter polymorph-
isms of the genes encoding TNF-a and IL-1b are associated with
different psoriasis subgroups de®ned by early and late disease onset.
They also support the concept that these subgroups rather than
those de®ned by familial vs sporadic disease differ in their genetic
background (Jenisch et al, 1998). In addition, our study underlines
the importance of controlling for parameters such as gender, age at
onset, and family history, when investigating cytokine gene
polymorphisms in psoriasis, and offers some explanation for the
variation observed in previous studies with regard to the distribu-
tion of such polymorphisms among psoriatic patients (Arias et al,
1997; Hohler et al, 1997; Jacob et al, 1999; Reich et al, 1999).
From the results of linkage analyses neither TNFA nor IL1B
appear to represent major genes in psoriasis. The TNFA gene lies
outside the 60 kb critical interval between HLA-C and the HCR
gene on 6p21, which is suggested to contain the PSORS1 psoriasis
susceptibility locus (OMIM: *177900) (Nair et al, 2000). In light of
the observed association of TNFA and IL1B promoter polymorph-
isms with early and late onset psoriasis subgroups, respectively,
however, it is tempting to speculate that these polymorphisms may
act as disease modi®ers involved in the determination of disease
onset. Especially in the case of TNFA±238*2, the probable
association with very early disease onset (< 25 y), the pro-
in¯ammatory function in vitro, and the ®nding that this variant
allele is part of the psoriasis-associated haplotype at 6p21 (Hohler et
al, 1997; Jenisch et al, 1999) argue for a possible role in early disease
manifestation. Accordingly, the previous observation of an associ-
ation of HLA-Cw6 with early disease onset (Enerback et al, 1997)
may re¯ect linkage disequilibrium between HLA-Cw6 and
TNFA±238*2.
Clearly, there are several limitations to the ®ndings in this study.
With regard to the functional role of TNFA and IL1B promoter
polymorphisms, it has been shown that genetic relationships
between polymorphic cytokine alleles and cytokine production
may vary in patient groups compared with healthy controls (Koss et
al, 2000). In fact, Kaluza et al (2000) reported a decreased secretion
of TNF-a in PBMC cultures derived from psoriatic patients
carrying TNFA±238*2 in response to stimulation with anti-CD3
antibodies or streptococcal antigens. Therefore, further studies are
necessary to explore fully the relationship between TNFA
polymorphisms and TNF-a production in psoriasis. Also, it cannot
be excluded that the dysregulation of IL-1b and TNF-a observed
in psoriasis is related to other polymorphisms present in the IL1 and
TNFA genes, and that IL1B±511*1 and TNFA±238*2 alleles are
associated with psoriasis through linkage disequilibrium with such
polymorphisms. For example, a rare TNFA promoter variant (A at
±376), that occurs in strict linkage with TNFA±238*2, was recently
shown to introduce a binding site for the transcription factor
OCT1 and to alter gene expression in human monocytes (Knight et
al, 1999). Finally, association results obtained from case±control
studies might always be in¯uenced by population strati®cation.
Deviation from Hardy±Weinberg equilibrium at the TNFA±308
locus with under-representation of TNFA±308*2 homozygotes has
been observed in the control group collected by Hohler et al (1997)
and interpreted as evidence that these controls are not a represen-
tative population sample (Jacob et al, 1999). The ®nding of a similar
deviation in our large independent control sample and the
demonstration that carriage of TNFA±308*2 is associated with
fatal outcome of common infectious diseases, including meningo-
coccal disease in children (McGuire et al, 1994; Nadel et al, 1996),
however, point to negative selection as another possible explan-
ation for this phenomenon. Large-scale family-based association
studies are under way to support the association between psoriasis
and polymorphisms in the TNFA and IL1B cytokine genes.
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Figure 3. Frequency of TNFA±238 polymorphism depends on
age of onset in male patients with psoriasis. Male patients with
psoriasis were classi®ed in those with disease onset < 25 y, those with
disease onset between 25 y and 49 y, and those with disease onset > 49 y
of age. Bars represent the percentage of carriers of TNFA±238*2 in each
of these groups compared with male controls. n, number of individuals
investigated in each group.
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